Oral Session 3-8A ATL: Clinical practice

[OS3-8A-2] Proportion of CD4⁺CADM1⁺ population predicts disease progression in HTLV-1 AC and indolent ATL

Junya Makiyama¹, Seiichiro Kobayashi², Eri Watanabe³, Tomohiro Ishigaki^4,5, Toyotaka Kawamata¹, Makoto Nakashima⁶, Makoto Yamagishi⁶, Kazumi Nakano⁶, Arinobu Tojo^1,2, Toshiki Watanabe⁷, Kaoru Uchimaru^1,6 (1.Dpt. Hematology/Oncology, IMSUT Hospital, Tokyo, Japan, 2.Division of Molecular Therapy, IMSUT, 3.IMSUT clinical flow cytometry laboratory, 4.Dpt. Laboratory Medicine, IMSUT Hospital, 5.Division of Stem Cell Therapy, IMSUT, 6.Graduate School of Frontier Sciences, The University of Tokyo, 7.Dpt. Advanced Medical Innovation, St. Marianna University School of Medicine)